Report Search Results (Showing 1 to 20 of 30)	As of 22-Nov-2009
New Screen

All Reports | Brokerage Reports | Independent Reports

Release Date  Contributor Author Title Pages Price StarMine Author Rating More Info EPS Accuracy * Portfolio Return ** 10-Nov-09 Brean Murray & Co., Inc. Jose Haresco HOLX: Beats F4Q Estimates, but Guidance Disappoints for FY10 as Slow Growth Turns into No Growth 5 $10     View Abstract 10-Nov-09 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD, Andrey Glukhov CFA, Michael Gaugler, Daniel Fidell, Jose Haresco, Bret Jones Morning Insight (ERTS, GAME, NTES, PWRD, SNDA, MIPI, HYTM, HOLX, QSII, COMV, SWWC) 10 $25     View Abstract 9-Nov-09 Brean Murray & Co., Inc. Jose Haresco BEAT: MCOT Case Volume Grows 46% YoY Despite Revenue Impact of Lower Reimbursement; Lowering Estimates and Downgrading to Hold 5 $10     View Abstract 9-Nov-09 Brean Murray & Co., Inc. Eric M. Beder, Michael Gaugler, Daniel Fidell, Jose Haresco Morning Insight (BEAT, ANF, MFB, URBN, AEO, ANF, ARO, BEBE, CACH, GES, JCG, NWY, TRLG, URBN, WTSLA, YORW, NCOC, Water Works Weekly, Clean Energy Weekly Review, Utility Weekly Review) 15 $50     View Abstract 6-Nov-09 Brean Murray & Co., Inc. Jose Haresco VOLC: An Uneventful Quarter Has Us Looking Ahead to Sustained Profitability in 2010 5 $10     View Abstract 6-Nov-09 Brean Murray & Co., Inc. Jose Haresco OMPI: Seasonality Is a Double-Edged Sword; 3Q Miss Made Up For By Encouraging 4Q Guidance 4 $10     View Abstract 6-Nov-09 Brean Murray & Co., Inc. Eric M. Beder, Ryan Worst CFA, Andrey Glukhov CFA, Michael Gaugler, Daniel Fidell, Jose Haresco, Ling Wang CFA, Bret Jones, Jeremy Sussman Morning Insight (BEBE, AEO, ANF, ARO, URBN, WTSLA, CCC, FTEK, ECLP, VOLC, OMPI, ARIA, ATVI, SJI, IGT) 14 $50     View Abstract 5-Nov-09 Brean Murray & Co., Inc. Jose Haresco AMMD: 3Q Results Beat our Street-High Estimates; Management Guides Above Street as Upbeat Commentary on Growth Opportunities Dominates the Discussion 5 $10     View Abstract 5-Nov-09 Brean Murray & Co., Inc. Eric M. Beder, Jonathan M. Aschoff PhD, Andrey Glukhov CFA, Michael Gaugler, Daniel Fidell, Jose Haresco, Bret Jones Morning Insight (AWR, WRC, AMMD, PFWD, NKTR, CNSO, MDVN, SGMO, ELON, CHG, CNP, NST, NU, UIL, UTL, VVC, THQI) 16 $50     View Abstract 4-Nov-09 Brean Murray & Co., Inc. Jose Haresco VOLC: 3Q Earnings Preview: Expecting No Surprises 4 $10     View Abstract 4-Nov-09 Brean Murray & Co., Inc. Eric M. Beder, Jonathan M. Aschoff PhD, Michael Gaugler, Jose Haresco, Ling Wang CFA, Ananda Baruah, Jeremy Sussman Morning Insight (ANR, JRCC, PBI, MWA, TRLG, AEO, ANF, ARO, URBN, VOLC, ARIA, PARD) 11 $25     View Abstract 2-Nov-09 Brean Murray & Co., Inc. Jose Haresco ALGN: Management Meetings Focus on Growth Opportunities 5 $10     View Abstract 2-Nov-09 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD, Michael Gaugler, Daniel Fidell, Jose Haresco, Jeremy Sussman Morning Insight (CCC, Water Works Weekly, ALGN, ACI, UIL, Utility Weekly Review, Clean Energy Weekly Review) 13 $50     View Abstract 30-Oct-09 Brean Murray & Co., Inc. Jose Haresco CRDC: Dropping Coverage 4 $10     View Abstract 30-Oct-09 Brean Murray & Co., Inc. Jose Haresco PMTI: Third Quarter in Line with Estimates; Management Tone Improves 4 $10     View Abstract 30-Oct-09 Brean Murray & Co., Inc. Ryan Worst CFA, Andrey Glukhov CFA, Daniel Fidell, Jose Haresco, Ling Wang CFA, Bret Jones, Ananda Baruah Morning Insight (AMSC, BYI, PFWD, ATHN, PMTI, IMGN, EK, IM, AVT, MCRS) 13 $50     View Abstract 23-Oct-09 Brean Murray & Co., Inc. Jose Haresco ALGN: Align Beats as Invisalign Teen Successfully Begins to Mitigate Seasonality; Raising Estimates and Target Price 5 $10     View Abstract 23-Oct-09 Brean Murray & Co., Inc. Jose Haresco, Bret Jones, Ananda Baruah, Jeremy Sussman Morning Insight (CNX, ALGN, CPSI, WDC, XRX) 8 $25     View Abstract 22-Oct-09 Brean Murray & Co., Inc. Jose Haresco OMPI: Pullback Offers Entry Ahead of the Quarter; Raising Target Price to $15 4 $10     View Abstract 22-Oct-09 Brean Murray & Co., Inc. Jose Haresco STJ: St. Jude Offers an Upbeat Long-term View; Near-term Risks Remain, However 4 $10     View Abstract Next 10